- Home
- TLSA vs MAIA Comparison
TLSA vs MAIA Comparison
Compare TLSA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | MAIA |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 44.9M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TLSA | MAIA |
|---|---|---|
| Price | $1.49 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 414.9K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.87 |
| 52 Week High | $2.60 | $2.74 |
Technical Indicators
Market Signals| Indicator | TLSA | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 63.82 |
| Support Level | $1.45 | $1.13 |
| Resistance Level | $1.62 | $1.75 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 35.58 | 69.35 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.